AbbVie Drops Case Blocking EMA Transparency Initiative, Intermune Continues Fight

Drug Industry Daily
A A
AbbVie has dropped two lawsuits against the EMA over the agency’s plans to disclose clinical trial data for its rheumatoid arthritis drug Humira (adalimumab), clearing a major hurdle for the EMA’s transparency initiative.

To View This Article:

Login

Subscribe To Drug Industry Daily